Are pan-coronavirus vaccines an achievable goal in providing broad protection against human coronaviruses?

NewsGuard 100/100 Score

In a recent study published in the journal Cellular & Molecular Immunology, scientists from University College London reviewed the current achievements in the development of a pan-coronavirus vaccine and the challenges involved in limiting the transmission of Middle East respiratory syndrome coronavirus (MERS-CoV), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and four other human coronaviruses.

Study: In search of a pan-coronavirus vaccine: next-generation vaccine design and immune mechanisms. Image Credit: LookerStudio/Shutterstock.comStudy: In search of a pan-coronavirus vaccine: next-generation vaccine design and immune mechanisms. Image Credit: LookerStudio/


Although the coronavirus disease 2019 (COVID-19) pandemic has been one of the biggest global public health crises in the last few decades, the concerted efforts worldwide in developing effective vaccines have highlighted the importance of understanding the immunological basis of developing resistance against respiratory viruses.

While the global morbidity and mortality rates associated with the pandemic have been staggering, the COVID-19 vaccines have also significantly reduced the spread of the virus and prevented a substantial number of deaths.

Since coronaviruses have been responsible for the three major pandemics in the last twenty years, developing a pan-coronavirus is essential.

Pan-coronavirus vaccine

The current vaccines against SARS-CoV-2 and other coronaviruses that largely consist of the antigenically variant spike glycoprotein are specific to species and sometimes even to variants and elicit minimal cross-reactive immune responses against the coronavirus family's other variants or viral species.

A pan-coronavirus approach aims to develop a vaccine that effectively protects against infections or severe disease caused by any coronavirus family viruses.

The four seasonal human coronaviruses (HCoVs) OC43, 229E, NL63, HKU1, MERS-CoV, and SARS-CoV-2 are responsible for a significant portion of the economic health burden worldwide.

COVID-19 continues to present long-term health burdens due to long coronavirus disease (long COVID), which affects multiple organ systems and results in persistent fatigue, myalgia, dyspnea, and neurological impairments that further impact the individual’s life.

Many of these coronaviruses also have animal reservoirs, presenting the constant danger of emergent variants with higher virulence.

The Omicron variant of SARS-CoV-2 with novel mutations that help evade existing vaccine-induced immunity also highlighted the need for a pan-coronavirus vaccine that circumvents the requirement of updated vaccines that can only combat each emergent variant, reducing development costs and providing wide-scale protection against coronaviruses.

Current vaccine challenges

The review addressed a comprehensive list of the limitations of the current SARS-CoV-2 vaccines that need to be discussed during the development of pan-coronavirus vaccines. Some of these challenges include limitations in blocking asymptomatic infections that continue to cause viral transmission, inadequate mounting of immune responses in non-seroconverters such as those with inborn immunological errors, lack of durability of the immune response, absence of mucosal administrative routes that can increase vaccine uptake in the population, and the limited cross-reactive immunity of existing vaccines.

The scientists believe that the ideal pan-coronavirus vaccine should address these limitations by offering durable immunity against a wide range of Coronaviridae viruses in people of all age groups and prevent viral shedding, infection, or onward transmission of the virus.

The ideal vaccine would also provide lifelong immunity after a specific number of doses. Furthermore, vaccine design and development also need to involve a thorough understanding of the complex immunological responses that contribute to the most effective protection against coronaviruses, such as the contributions of non-neutralizing antibodies, natural killer cells, and T-cell responses.

Approaches to developing pan-coronavirus vaccines

Additionally, the researchers discussed in detail some pan-coronavirus vaccine approaches that are either in the preclinical stages or being clinically tested.

Numerous vaccines that use ferritin or mosaic nanoparticles for vaccine delivery and target either the receptor binding domain or the spike protein region of β-coronavirus or sarbecovirus are in the preclinical stages of development.

Another approach involves using vaccine antigens consisting of either a consensus sequence or a string of conserved B and T-cell epitopes.

Other approaches to pan-coronavirus vaccine development include the use of computationally designed antigens using bioinformatics methods, the inclusion of antigens for eliciting antibody and T-cell responses in the same messenger ribonucleic acid (mRNA) vaccine, the use of the S2 subunit alone to elicit a stronger vaccine response, and many more vaccine types.

The broadly reactive vaccines that are currently in the clinical trial stage include a ferritin nanoparticle platform, an enveloped vaccine with a virus-like particle, a self-amplifying mRNA vaccine, and a live-attenuated vaccine against parainfluenza viruses.


Overall, the scientists provided a detailed overview of the current state of pan-coronavirus vaccine development.

They also discussed many of the shortcomings of the currently used coronavirus vaccines that need to be addressed in the pursuit of developing a pan-coronavirus vaccine that can provide broad protection against a wide range of human coronaviruses.

Journal reference:
Dr. Chinta Sidharthan

Written by

Dr. Chinta Sidharthan

Chinta Sidharthan is a writer based in Bangalore, India. Her academic background is in evolutionary biology and genetics, and she has extensive experience in scientific research, teaching, science writing, and herpetology. Chinta holds a Ph.D. in evolutionary biology from the Indian Institute of Science and is passionate about science education, writing, animals, wildlife, and conservation. For her doctoral research, she explored the origins and diversification of blindsnakes in India, as a part of which she did extensive fieldwork in the jungles of southern India. She has received the Canadian Governor General’s bronze medal and Bangalore University gold medal for academic excellence and published her research in high-impact journals.


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Sidharthan, Chinta. (2024, January 03). Are pan-coronavirus vaccines an achievable goal in providing broad protection against human coronaviruses?. News-Medical. Retrieved on April 20, 2024 from

  • MLA

    Sidharthan, Chinta. "Are pan-coronavirus vaccines an achievable goal in providing broad protection against human coronaviruses?". News-Medical. 20 April 2024. <>.

  • Chicago

    Sidharthan, Chinta. "Are pan-coronavirus vaccines an achievable goal in providing broad protection against human coronaviruses?". News-Medical. (accessed April 20, 2024).

  • Harvard

    Sidharthan, Chinta. 2024. Are pan-coronavirus vaccines an achievable goal in providing broad protection against human coronaviruses?. News-Medical, viewed 20 April 2024,


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Research confirms no association between SARS-CoV-2 and childhood asthma diagnoses